Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFranck MorschhauserMSMartijn SimonsAGAnna Gittfried

Discussion

Loading...

Member takes

Overview

Analysis shows similar progression-free survival and patient-reported outcomes for axi-cel in R/R LBCL, suggesting broad applicability.

Key Points

  • Progression-free survival rates were similar in patients treated with axi-cel regardless of ASCT eligibility across two trials.
  • Patient-reported outcomes indicated consistent HRQoL patterns after treatment in both ZUMA-7 and ALYCANTE populations.
  • Data pooled from ZUMA-7 and ALYCANTE evaluate the efficacy and safety of axi-cel as a second-line therapy in R/R LBCL patients.
  • These findings support the use of axi-cel beyond traditional transplant eligibility criteria, highlighting its effectiveness.

Cite This Study

Morschhauser et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df44https://doi.org/10.1182/blood-2025-3714
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  2. 2Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma2025
  3. 3Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025
  4. 4Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel2025
  5. 5Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study2025